Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002

Trial Profile

Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Esmirtazapine (Primary)
  • Indications Insomnia
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 09 Oct 2009 Schering-Plough added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top